Upload
others
View
20
Download
0
Embed Size (px)
Citation preview
TRANSLATIONAL MEDICINEIN ZURICH
CONFERENCE BOOKLET
JANUARY 22ND, 2018TECHNOPARK ZURICH
A LIFE SCIENCE ZURICH BUSINESS NETWORK INITIATIVE
#LSZIMPACT
© N
orbe
rt W
ey, U
SZ
INNOVATION
MADE IN
ZURICH
WELCOME TO ZURICH
Zurich offers a vibrant and dynamic ecosystem for
the entrepreneurial scene, especially in the field of
life sciences. The foundations for this are laid by the
two top-class universities, the University of Zurich
and the ETH Zurich. Together with the University
Hospitals and the Zurich University of Applied
Sciences (ZHAW), academic medicine covers a broad
spectrum of scientific disciplines and provides cut-
ting-edge transdisciplinary research – one important
aspect of innovation. In addition, internationally re-
nowned companies of the life science industry have
settled in the Zurich region. This environment is seeing
a growing number of spin-outs from the Universities in
the pharmaceutical, biotechnology and medical tech-
nology sectors. Thanks to its combination of academic
excellence, entrepreneurship and innovation, financial
strength, outstanding accessibility, a high level of se-
curity as well as a healthy economy, Zurich is one of
the leading centers of life sciences in Europe.
A core task of academic medicine is to design the
medicine of the future using innovative concepts,
new technologies and transdisciplinary know-how to
generate sustainable value for health promotion, health
prevention and the whole cycle of care. Decisive for
that is to make new technologies and therapies appli-
cable for patients and public. Translational Medicine
deals with the transition of new insights and products
from basic research and industrial development into
clinical application and is therefore an essential deter-
minant for cross-linking basic research and medical
use. In short, translational research builds the bridge
from bench-to-bedside and back. The close interaction
between universities, private companies and the pub-
lic sector provides ideal conditions for young entrepre-
neurs to perform this translation.
The first translational medicine conference «Life
Science Zurich Impact» promotes such interactions
by providing scientists from academia and industry a
platform to present their life sciences projects to po-
tential collaboration partners as well as to investors. It
is therefore an excellent opportunity to accelerate
the development of novel therapeutic strategies
and innovative concepts of health prevention for
the benefit of numerous patients in our aging society.
We take this occasion to wish the participants an excit-
ing conference with plenty of opportunities to expand
your personal network with valuable contacts.
Carmen Walker Späh
Government Councillor
Canton of Zurich
Head of the Depart-
ment for Economic
Affairs
Prof. Dr. Christoph Hock
Vice President for
Medicine
University of Zurich
© Z
üric
h To
uris
mus
AIM AND SCOPE OF THE CONFERENCE
Life Science Zurich Impact – Translational Medicine in Zurich is a one-day multi-track meeting providing
scientists from academia and industry a platform to present their life sciences projects to potential collab-
oration partners as well as investors. The focus lies on early stage projects in pharma, biotech and medtech in
the fields of cancer, immunology & infection and neurosciences. We believe that early interaction with potential
partners is a key success factor for research groups, young entrepreneurs and industry.
1-TO-1 PARTNERING
To promote networking, and to faciltiate the formation of new contacts and the initiation of new projects are major
goals of Life Science Zurich Impact – Translational Medicine in Zurich.
To this end, pre-arranged 20 minutes face-to-face meetings are coordinated by Enterprise Europe Network.
Register now for matchmaking at the conference webpage. During the conference, Nicolas Lentze from Enter-
prise Europe Network will offer on-site support.
INDUSTRY EXHIBITION
Please visit the booths in the exhibition area to learn about innovative products and services!
Open during the entire conference.
CONTACTS
General questions about the eventDanielle Spichiger
Business & Economic Development
Canton of Zurich
+41 43 259 49 86
Silvie Cuperus
Life Science Zurich
+41 44 635 35 01
Industry exhibitionTo book a booth in the exhibition area please contact
Angelika Rüegg
For questions about delivery/installation of material
please contact Marianna Lutz (Eventmanagement,
Stiftung TECHNOPARK® Zürich)
+41 44 445 10 00
Partnering and matchmakingNicolas Lentze
Enterprise Europe Network Switzerland
+41 58 469 07 59
I CAN READ 5,000 NEW MEDICAL STUDIES A DAY AND STILL SEE PATIENTS.
With Watson and IBM Services, doctors on 5 continents can use clinical guidelines, medical literature, and data from patients to help them give advanced and personalized care. Find out more at ibm.com/you This is healthcare to the power of IBM.
IBM and its logo, ibm.com and Watson are trademarks of International Business Machines Corp., registered in many jurisdictions worldwide. See current list at ibm.com/trademark. Other product and service names might be trademarks of IBM or other companies. ©International Business Machines Corp. 2017.
IBM and its logo, ibm.com and Watson are trademarks of International Business Machines Corp., registered in many jurisdictions worldwide. See current list at ibm.com/trademark. Other product and service names might be trademarks of IBM or other companies. ©International Business Machines Corp. 2017.
ORGANIZERS
The Life Science Zurich Business Network is an
independent, non-profit association comprising play-
ers from universities, industry, economic develop-
ment, business clusters, and technology transfer. It
represents the life sciences cluster in the Zurich area
and supports and stimulates networking and collab-
orations between industry, academia, and the public
sector in the Zurich area and companies and organi-
sations abroad.
PARTNERS
SPONSORS Gold SPONSORS Silver
Canton of ZurichDepartment for Economic Affairs Offi ce for Economy and Labour
IBM Research
Pho
togr
aphy
: Oliv
ia J
anet
t
WE THANK OUR PARTNERS AND SPONSORS FOR THEIR ENGAGEMENT AND SUPPORT!
BioResearch
Advancing Research withBiologically Relevant Solutions
Our products and services support researchers through their cell biology process, from early research through drug discovery and cell therapy. We offer biologically relevant tools to quickly and easily generate decision driving data.
– Primary Cells and Media – Media and Reagents – Mycoplasma Detection and Prevention – Cell Analysis – Transfection – BioAssay Products and Services – Electrophoresis and Analysis
www.lonza.com/research© 2015 Lonza
GENERAL INFORMATION
Meeting venueTechnopark Zürich is located at the heart
of Zurich West
Technoparkstrasse 1, 8005 Zürich
www.technopark.ch
By car from
• St. Gallen/airport via Rosengartenstrasse,
Escher-Wyss-Platz (bridge), Hardturmstrasse,
Förrlibuckstrasse, Duttweilerstrasse (Toni-Molkerei
building), Pfingstweidstrasse, Technoparkstrasse.
• Bern/Basel: via Pfingstweidstrasse, Technopark-
strasse.
• Lucerne/Chur: via Hardbrücke, Geroldstrasse exit
ramp, Schiffbau, Technoparkstrasse.
• Zurich: via Escher-Wyss-Platz, Hardstrasse or Hard-
turmstrasse
Limited parking space is available at extra cost on
site. Further parking space is available in walking
distance:
• Parkhaus Pfingstweid (Welti-Furrer-Areal,
Pfingstweidstrasse 1, 8005 Zürich).
• Parkhaus P-West (Förrlibuckstr. 151, 8005 Zürich)
The site is best reached by public transport
• Tram no. 4 to Technopark, walk 2 minutes
• Tram no. 17 to Förrlibuckstrasse, walk 4 minutes
• Tram no. 13 or 17 to Escher-Wyss-Platz, walk
8 minutes
• Bus no. 33 to Schiffbau, walk 4 minutes
• Bus no. 72 to Schiffbau, walk 4 minutes
• S-Bahn lines S3 / S5 / S6 / S7 / S9/ S12 / S15 / S16
to Hardbrücke, walk 8 minutes
Internet accessVia WIFI/hotspot in public areas and event rooms.
Further information will be provided at the event.Stiftung TECHNOPARK® ZürichTechnoparkstrasse 1 | CH-8005 Zürich Tel +41 44 445 10 00 | [email protected] www.technopark.ch
© Copyright TECHNOPARK® Immobilien AG, Technoparkstasse 1, 8005 Zürich 14. Oktober 2014
So finden Sie uns
Anreise mit öffentlichen Verkehrsmitteln › Förrlibuckstrasse (VBZ): Tram Nr. 17 (Fussweg Technopark
strasse, gestrichelte Linie, durch Sulzer EscherWyssAreal, 4 Min.)*
› Escher-Wyss-Platz (VBZ): Tram Nr. 4, 13 oder 17 (Fussweg, entlang Hardstrasse / Schiffbaustrasse, gestrichelte Linie, Technoparkstrasse, 8 Min.)*
› Technopark (VBZ): Tram 4 bis Technopark (Fussweg, gestrichelte Linie, Technoparkstrasse, 1 Min.)*
› Bus (VBZ) Nr. 33 bis Station Schiffbau (Fussweg, gestrichelte Linie, Technoparkstrasse, 4 Min.)*
› Bus (VBZ) Nr. 72 bis Station Schiffbau (Fussweg, gestrichelte Linie, Technoparkstrasse, 4 Min.)*
› S-Bahn Linien S3 / S5 / S6 / S7 / S9 / S12 / S15 / S16 (alle Linien mit Verbindungen zu ZürichHB) oder diverse SBBLinien von und nach ZürichHB bis Station Hardbrücke (Fussweg entlang Hardstrasse, gestrichelte Linie, Technoparkstrasse, 8 Min.)*
* Taktfahrplan: zwischen 6.00 – 20.00 Uhr, alle 7.5 Min
Anreise mit privaten VerkehrsmittelnSehr beschränkte Anzahl gebührenpflichtiger Parkplätze in der Tiefgarage TECHNOPARK® Zürich, weitere Parkhäuser: P Pfingstweid und P West › von St.Gallen / Flughafen: über Rosengartenstrasse, Escher
WyssPlatz(Brücke), Hardturmstrasse, Förrlibuckstrasse, Duttweilerstrasse (ToniAreal / ZHdK), Pfingstweidstrasse (ausgezogene Linie), Technoparkstrasse (gestrichelte Linie)
› von Bern / Basel: über Pfingstweidstrasse (ausgezogene Linie), Technoparkstrasse (gestrichelte Linie)
› von Luzern/Chur: über Hardbrücke, Geroldrampe, Pfingstweidstrasse (ausgezogene Linie), Technoparkstrasse (gestrichelte Linie)
› von der City: via EscherWyssPlatz, Hardstrasse oder Hardturmstrasse (ausgezogene Linie)
› vom P+R Hardturm: Tram 17 (VBZ) nach Förrlibuckstrasse
Wegfahrt vom TECHNOPARK® Richtung Pfingstweidstrasse: nach Bern/BaselWegfahrt vom TECHNOPARK® Richtung Förrlibuckstrasse: nach St.Gallen/Flughafen/Luzern/Chur und Zürich-City
Eingang
Förrlibuckstrasse
Escher-Wyss-Platz
Giessereistrasse
Pfingstweidstrasse
Duttw
eile
rstra
sse
Dut
twei
lerb
rück
e
Hohlstrasse
Tech
nopa
rkst
rass
eFörrlibuckstrasse
Hards
trass
e
Heinrichstrasse
Josefstrasse
Limm
atstrasse
Turbinen-platz
Schiffbaustrasse
Geroldrampe
Hardturmstrasse
VBZ
Schiffbau
Technopark
TechnoparkZürich
Hardbrücke (S-Bahn)
VBZ
VBZ
VBZ
P
P
P West
Pfingstweid
LuzernChur N
St. GallenFlughafen
BernBasel
LimmatFörrlibuckstrasse
Conference Webpage:https://lsz-impact2018.b2match.io
#lszimpact
Johnson & Johnson Innovation Centres A flexible approach to advancing early-stage innovation
Johnson & Johnson Innovation seeks to find the best science and technology partners, no matter where they are, to solve the greatest unmet needs of our time. Positioned at the heart of the world’s most creative science hubs, we take a collaborative approach to partnering to advance early-stage innovation.
The next breakthrough idea can come from anywhere. Maybe it will come from you.Together we can transform ideas into healthcare solutions that change lives.
BECAUSE A GREAT IDEA CAN COME FROM ANYWHERE
@jnjinnovation
©Johnson & Johnson Innovation LLC 2017.
www.jnjinnovation.com
786207158-001_Innovation Press Ads_108x145_UK.indd 1 12/09/2017 13:41
8:00 - 9:00 Registration
9:00 - 9:10 Welcome Danielle Spichiger, Director Cluster Life Sciences, Business and Economic Development, Canton of Zurich; President, Life Science Zurich
Business Network Introduction Prof. Christoph Hock, Vice President Medicine, University of Zurich
9:10 - 9:40 Novel technologies create new molecules for accessing cutting-edge therapeutic concepts Prof. Andreas Plückthun, Professor of Biochemistry, UZH; Co-founder of Morphosys, Molecular Partners, G7/Heptares-Zurich
9:40 - 10:10 Lost in medical translation? Prof. Ralph Müller, Professor and Head Laboratory for Bone Biomechanics, ETH Zurich; Co-founder b-cube AG / Pearltec AG
10:10 - 10:30 Coffee break
10:30 - 12:00 Parallel sessions morning Overview + 4-5 short presentations + wrap-up and summary
CANCER IMMUNOLOGY & INFECTION NEUROSCIENCE
Prof. Bernd Bodenmiller, UZH
PD Dr. Irene Burger, USZ
Prof. Manfred Claassen, ETH Zurich
Prof. Anne Müller, UZH
Dr. Christian Rommel (CHAIR), Global Head of Oncology, Roche
Prof. Burkhard Becher, UZH
Dr. Mattias Ivarsson, CEO & Founder Inositec
Prof. Roland Martin (CHAIR), UZH & Wyss Zurich
Dr. Roch Ogier, Therapy Development Accelerator UZH
Jean-Philippe Tripet, Founder & Chairman ARAVIS
Prof. Alexandra Trkola, UZH
Prof. Frédéric Allain, ETH Zurich
PD Dr. Patrick Freund, UZH
Dr. Jan Grimm, CSO Neurimmune
Prof. Sebastian Jessberger, UZH
Prof. Lawrence Rajendran, UZH
Prof. Martin Schwab (CHAIR) / Dr. Roman Willi, NovaGo
12:00 - 13:30 Lunch break
TRANSLATIONAL MEDICINE IN ZURICH January 22nd, 2018, Technopark Zurich
MORNING PROGRAMME
Canton of ZurichDepartment for Economic Affairs Offi ce for Economy and Labour
13:30 - 15:00 Parallel sessions afternoon Overview + 4-5 short presentations + wrap-up and summary
CANCER IMMUNOLOGY & INFECTION NEUROSCIENCE
Dr. Chad Brokopp, CEO MabImmune
PD Dr. Stefano Ferrari, UZH
Dr. Christian Leisner, CEO CDR Life
PD Dr. Raffaella Santoro, UZH
Dr. Anne Schmidt, CEO Elthera
Prof. Simone Schürle (CHAIR), ETH Zurich
Prof. Onur Boyman (CHAIR), USZ
Dr. Louise Jopling, Senior Director Immunology Scientific Innovation, Johnson & Johnson Innovation
Dr. Jan Kisielow, ETH Zurich
Prof. Andreas Lutterotti, UZH & Wyss Zurich
Jean-Philippe Tripet, Swiss Entrepreneurs Fund
Dr. Tomas de Wouters, CEO PharmaBiome
Prof. Sven Hirsch, ZHAW Life Sciences and Facility Management
Dr. Sanjay Keswani, Global Head of Neuroscience, Ophthalmology & Rare Diseases, Roche
Prof. Isabelle Mansuy (CHAIR), UZH
Prof. Boris Quednow, UZH
Prof. Markus Rudin, ETH Zurich
Dr. Bechara Saab, CEO & Chief Scientist, Mobio Interactive
15:00 - 15:30 Coffee break
15:30 - 16:00 Hackers, Hipsters, Hustlers: Bio-Entrepreneurs in Zurich Prof. Roger Nitsch, Professor and Director Institute for Regenerative Medicine, UZH; Founder and President of the Board, Neurimmune
16:00 - 16:30 Cognitive Computing in Life Sciences Dr. Costas Bekas, Manager of Foundations of Cognitive Computing Group, IBM Research-Zurich
16:30 - 17:15 Panel discussion «Apple, IBM, Google and Co: the next Big Pharma?» Dr. Costas Bekas, Manager of Foundations of Cognitive Computing Group, IBM Research-ZurichNathan Hubbard, Director of Digital and PHC Partnering, Roche PartneringDr. Denis Schapiro, winner of the first «UZH BioEntrepreneur-Fellowship» 2017 Prof. Effy Vayena, Professor of Bioethics and Health Policy, ETH Zurich moderated by Barnaby Skinner, Data Journalist, Tamedia
17:15 - 17:30 Summary and Outlook Prof. Ernst Hafen, Institute of Molecular Systems Biology, ETH Zürich, President of BIO-TECHNOPARK Schlieren-Zurich and
MIDATA Genossenschaft Closing remarks Prof. Detlef Günther, Vice President Research and Corporate Relations, ETH Zurich
17:30 - 18:30 Apéro
TRANSLATIONAL MEDICINE IN ZURICH January 22nd, 2018, Technopark Zurich
AFTERNOON PROGRAMME
Canton of ZurichDepartment for Economic Affairs Offi ce for Economy and Labour
KEYNOTE SPEAKERS
Andreas Plückthun, a biochemist fo-
cused on the field of protein enginee-
ring, has been honoured by numerous
prestigious international awards. His
research contributed to enabling the
emergence of antibody engineering
and directed evolution. Studies on syn-
thetic antibodies have led to the first
fully synthetic antibody library. Moreo-
ver, he is cofounder of the biotechnolo-
gy companies Morphosys AG (Martins-
ried, Germany), Molecular Part ners AG
(Zurich-Schlieren, Switzer land) and G7
Therapeutics, recently acquired by Hep-
tares Therapeutics ( Zurich-Schlieren,
Switzerland).
Andreas Plückthun is a professor in the
Department of Biochemistry at the Uni-
versity of Zurich, and has been elected
member of the German Academy of
Science. He is one of the most highly
cited scientists at UZH of all fields, and
internationally in the field of protein re-
search.
Ralph Müller is a full Professor of Bio-
mechanics at the Department of Health
Sciences and Technology at ETH Zurich.
He studied electrical engineering at
ETH Zurich, where he also received his
doctoral degree in 1994. Professor Mül-
ler‘s research employs state-of-the-art
biomechanical testing and simulation
techniques as well as novel bioima-
ging and visualisation strategies for
musculoskeletal tissues. Today, these
techniques are successfully employed
for the quantitative assessment and
monitoring of structure function relati-
onships in tissue regeneration, growth
and adaptation. In 2008, Ralph Müller
founded two spin-off companies, Pearl-
tec AG, developing and marketing novel
patient positioning systems for medical
imaging procedures using patented
technology from ETH Zürich, and b-cu-
be AG, since 2013 a subsidiary of Scan-
co Medical AG.
Roger M. Nitsch, a neuroscientist
with a background in medicine, is re-
cognized as a pioneer of disease-mo-
difying therapeutic approaches for
neurodegenerative diseases with more
than 30 years of experience in Alzhei-
mer’s disease research. His main re-
search focus is the immunotherapy of
neurodegenerative diseases. He spe-
arheaded the development of Aduca-
numab, a human antibody for the tre-
atment and prevention of Alzheimer’s
disease. In addition, Roger M. Nitsch
is a founder and president of Neurim-
mune a biopharmaceutical company
dedicated to the development of im-
munotherapeutics for the treatment
and prevention of human disorders
with high unmet medical needs.
Costas Bekas is managing the Foun-
dations of Cognitive Computing group
at IBM Research-Zurich. He received
B. Eng., Msc and PhD diplomas, all
from the Computer Engineering & In-
formatics Department, University of
Patras, Greece, in 1998, 2001 and 2003
respectively. Between 2003-2005,
he worked as a postdoctoral associ-
ate with Professor Yousef Saad at the
Computer Science & Engineering De-
partment, University of Minnesota,
USA. He has been with IBM since Sep-
tember 2005. Dr. Bekas‘ main research
interests span cognitive computing,
massive scale analytics and energy
aware algorithms and architectures. Dr.
Bekas is a recipient of the PRACE 2012
award and the ACM Gordon Bell 2013
and 2015 prizes.
PANEL DISCUSSION
MODERATION
Costas Bekas is managing the Foundations
of Cognitive Computing group at IBM Re-
search-Zurich. He is also a keynote speaker at
this conference and presented in the respec-
tive section of this booklet.
Nathan Hubbard is the Director of Digital
and Personalized Health Care Partnering for
Roche, where he is responsible for the iden-
tification and execution of digital healthcare
partnerships as part of the implementation
of Roche’s personalized health care strategy.
Nathan joined Roche in August of 2016 and
has completed business development collab-
orations with Vital Art and Science and GNS
Healthcare among others. Nathan has held
a number of roles across the pharmaceutical
value chain within strategy, business devel-
opment, finance, sales, and marketing with
a focus on oncology and neurology. Nathan
received an MBA from Stanford University,
where he focused on general management,
and holds a BA in Economics with minors
in English Literature and Psychology from
DePauw University.
Denis Schapiro studied Technical Biology at
the Universities of Stuttgart and Harvard work-
ing with Alfred Goldberg (Proteome Dynam-
ics) and Peter Sorger (Signalling in Rheuma-
toid Arthritis). Moving from wet lab to dry lab,
he joined the Complex Systems Modelling
group as an intern at Bayer AG.
Afterwards he joined the group of Bernd
Bodenmiller (University of Zurich) to develop
computational and experimental methods for
spatial proteomics. The developed Imaging
Mass Cytometry™ technology as well as the
analysis software histoCAT™ are both today
routinely used in world leading research insti-
tutes for basic and translational research.
He was awarded the first UZH BioEntrepre-
neur-Fellowship to combine Cytometry and
Pathology in a user-friendly computational
framework which he is currently using as a
platform for biomarker discovery based on
spatial localization of cell types, tissue organi-
zation and cellular neighbourhoods.
Effy Vayena is a Professor of Bioethics at the
Swiss Institute of Technology and a Visiting
Professor at the Center for Bioethics at Har-
vard Medical School and a Faculty Associate
at the Berkman Klein Center for Internet &
Society at Harvard University. She is a social
historian with a PhD in Medical History from
University of Minnesota and a renowned ex-
pert at the intersection of medicine, data, and
ethics. Her work focuses on societal issues
of data and technology. At the University of
Zurich, she cofounded and coordinated the
PhD program in Biomedical Ethics and Law.
She also founded the Health Ethics and Poli-
cy Lab to tackle pressing questions that arise
through technological advances in healthcare
and research. She has previously worked with
the WHO, Wellcome Trust, OECD, Common-
wealth Fund, Chatham House, and academ-
ic institutions and governments around the
world.
Barnaby Skinner studied history at the University
of Basel, focussing on the Industrial Revolution in the
19th Century and its social and economic impacts. As
a journalist writing for the «SonntagsZeitung» and the
«Tages-Anzeiger» he has shifted his attention to the
Digital Revolution, using data driven technologies to
tell stories and explore, how the Internet is impacting
society.
MissionThe Swiss Industry Science Fund (SISF) promotes scientific excellence in research and education in Switzerland, within the scope of its member companies.
OrganizationThe SISF is an unregistered partnership of the following member companies (listed alphabetically): BASF, Novartis, Roche, Syngenta.They meet quarterly to discuss and decide on applications for support.The SISF provides financial support for selected initiatives meeting the following criteria:• Selected scientific conferences, organizations, awards and special events in basic and applied research,
for education and further development of students and scientists.• Scientific areas covered include biology, chemistry and associated disciplines, with a focus on pharma-
ceutical R&D, life sciences and material sciences.• Events must take place in Switzerland or nearby regions, and call for a substantial and active participati-
on of Swiss-based scientists.• Preference will be given to events open to broad, rather than local participation.
More information can be found at www.sisf.info.